Souhaitez-vous accéder aux communiqués récents ?

WHITE PLAINS, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Iantrek, Inc., a pioneer and leader in bio-interventional ophthalmic surgery (BIOS), today announced the introduction and US controlled release...

BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a...

Biotech and healthcare innovators are advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global ac

Artelo Biosciences (NASDAQ: ARTL) enters ophthalmology space with a fully funded evaluating ART27.13 in glaucoma patients.

GRF partners with Alcon to launch Spanish glaucoma education resources, including the first Spanish audiobook, for Hispanic communities.

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Glaucoma - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report provides a thorough analysis of over 100...

ALISO VIEJO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational...

ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company’s Chief...

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Corneal Edema Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added...

First-in-Human (FIH) Trial at 36 Months: 37% reduction in mean intraocular pressure (IOP) in evaluable patients across all dose groups with 95% of patients off all topical IOP-lowering drops100% of...